The company had posted a consolidated net profit of Rs 801.18 crore in the same period of the preceding fiscal, Aurobindo Pharma said in a regulatory filing.
Revenue from operations declined by 1 per cent to Rs 6,002.2 crore as against Rs 6,064.8 crore in the same period of last financial year.
Molnupiravir was earlier approved under Emergency Use Authorisation from the Central Drugs Standard Control Organisation.
While Aurobindo Pharma is recalling Cyanocobalamin Injection, which is used to treat and prevent lack of vitamin B12, Mumbai-based Sun Pharma is recalling a drug used to increase the production of natural tears in eyes.
The action follows the recent inspection of the facility by the USFDA in August 2021, the drugmaker said in a stock exchange filing.
Markets were closed for the Diwali vacation since Thursday. How investors react on Monday would depend on what they see as a priority.
The Mumbai-based company's product is the generic version of Viatris Specialty LLC's Revatio